OptimizeRx (NASDAQ:OPRX) Announces Earnings Results, Misses Expectations By $0.03 EPS

OptimizeRx (NASDAQ:OPRX) released its quarterly earnings results on Wednesday. The company reported $0.13 earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.03), Zacks reports. OptimizeRx had a net margin of 4.66% and a return on equity of 9.44%.

OptimizeRx Trading Down 4.3%

OPRX stock traded down $0.40 during trading on Wednesday, hitting $8.95. The company had a trading volume of 377,700 shares, compared to its average volume of 350,808. The firm has a 50-day moving average price of $8.40 and a 200-day moving average price of $7.25. OptimizeRx has a 12 month low of $4.54 and a 12 month high of $16.37. The company has a quick ratio of 5.58, a current ratio of 5.58 and a debt-to-equity ratio of 0.14. The stock has a market cap of $168.58 million, a price-to-earnings ratio of 38.91 and a beta of 1.20.

Wall Street Analyst Weigh In

A number of equities analysts have commented on OPRX shares. Citizens Jmp boosted their price objective on OptimizeRx from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research note on Friday, August 14th. Weiss Ratings upgraded OptimizeRx from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, August 25th. Wall Street Zen cut OptimizeRx from a “strong-buy” rating to a “buy” rating in a report on Monday, July 20th. B. Riley Financial upped their price target on shares of OptimizeRx from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, September 29th. Finally, Stifel Nicolaus set a $12.00 price objective on shares of OptimizeRx in a report on Thursday, August 13th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, OptimizeRx currently has an average rating of “Moderate Buy” and an average target price of $11.57.

OptimizeRx Company Profile

OptimizeRx Corporation (NASDAQ: OPRX) is a digital health and life sciences technology company that helps pharmaceutical and biotechnology companies connect with healthcare professionals and patients. Its platform supports prescription-related communications, treatment access, affordability, adherence and patient engagement throughout the medication journey. The company provides solutions that can be integrated into electronic health records and other healthcare workflows. Its offerings include point-of-care messaging for healthcare professionals, patient support and savings programs, medication access tools, and data and analytics services designed to help life sciences companies communicate with relevant audiences and understand engagement.